LAP is activated via Toll-like receptors (TLRs) and immunoglobulin receptors, facilitating LC3-associated endocytosis (LANDO), a pathway involved in the clearance of Aβ and the amelioration of AD pathology [62,63]. The gene discussed is MAP1LC3A; the disease is Alzheimer disease.